6月22日，Kardigan盘前下跌9%，报20.02美元/股，成交额41.49万美元。消息面上，该股于6月19日以每股16美元的发行价登陆纳斯达克，IPO首日涨幅超42%，募资约4亿美元，定价位于发行区间上限。IPO交割预计于6月22日完成，经历首日大幅上涨后盘前出现回调。
Kardigan是一家临床阶段精准心血管疗法公司，旗下拥有Danicamtiv、Ataciguat及Tonlamarsen三项后期临床管线，均聚焦当前尚无获批疗法的心血管适应症，目前尚未实现商业化收入。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.